CA3233863A1 - Treatment methods for als patients - Google Patents

Treatment methods for als patients Download PDF

Info

Publication number
CA3233863A1
CA3233863A1 CA3233863A CA3233863A CA3233863A1 CA 3233863 A1 CA3233863 A1 CA 3233863A1 CA 3233863 A CA3233863 A CA 3233863A CA 3233863 A CA3233863 A CA 3233863A CA 3233863 A1 CA3233863 A1 CA 3233863A1
Authority
CA
Canada
Prior art keywords
subject
months
chlorite
als
crp
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3233863A
Other languages
English (en)
French (fr)
Inventor
Arasteh AZHIR
Michael S. Mcgrath
Bruce D. FORREST
Leah PRICE
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of California San Diego UCSD
Neuvivo Inc
Original Assignee
University of California San Diego UCSD
Neuvivo Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of California San Diego UCSD, Neuvivo Inc filed Critical University of California San Diego UCSD
Publication of CA3233863A1 publication Critical patent/CA3233863A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/20—Elemental chlorine; Inorganic compounds releasing chlorine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2835—Movement disorders, e.g. Parkinson, Huntington, Tourette

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Inorganic Chemistry (AREA)
  • Microbiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA3233863A 2021-10-04 2022-10-04 Treatment methods for als patients Pending CA3233863A1 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US202163252061P 2021-10-04 2021-10-04
US63/252,061 2021-10-04
US202263301476P 2022-01-20 2022-01-20
US63/301,476 2022-01-20
US202263302000P 2022-01-21 2022-01-21
US63/302,000 2022-01-21
PCT/US2022/077557 WO2023060097A1 (en) 2021-10-04 2022-10-04 Treatment methods for als patients

Publications (1)

Publication Number Publication Date
CA3233863A1 true CA3233863A1 (en) 2023-04-13

Family

ID=85804736

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3233863A Pending CA3233863A1 (en) 2021-10-04 2022-10-04 Treatment methods for als patients

Country Status (7)

Country Link
US (1) US12329776B2 (https=)
EP (1) EP4412624A4 (https=)
JP (1) JP2024533873A (https=)
AU (1) AU2022360976A1 (https=)
CA (1) CA3233863A1 (https=)
GB (1) GB2626503A (https=)
WO (1) WO2023060097A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017079161A2 (en) 2015-11-02 2017-05-11 Neuraltus Pharmaceuticals, Inc. Treatment of neurodegenerative disease with sodium chlorite
EP4412624A4 (en) 2021-10-04 2025-08-20 Neuvivo Inc TREATMENT METHODS FOR ALS PATIENTS
GB2637227A (en) 2022-05-19 2025-07-16 Neuvivo Inc Biomarkers for neurogenerative disease

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2011205095B2 (en) * 2004-02-03 2014-07-03 The Regents Of The University Of California Chlorite in the treatment of neurodegenerative disease
US7105183B2 (en) 2004-02-03 2006-09-12 The Regents Of The University Of California Chlorite in the treatment of neurodegenerative disease
US20060051790A1 (en) 2004-07-01 2006-03-09 The Regents Of The University Of California Genetic risk factor for neurodegenerative disease
JP5421590B2 (ja) 2005-05-18 2014-02-19 ノバルティス アーゲー 自己免疫および／または炎症性成分を有する疾患の診断および治療のための方法
JP5371443B2 (ja) 2005-12-22 2013-12-18 ニューラルタス ファーマシューティカルズ，インコーポレイテッド 亜塩素酸塩製剤、およびこの調製の方法と利用
WO2008042190A2 (en) 2006-09-29 2008-04-10 The Trustees Of The University Of Pennsylvania Detection of neurodegenerative disease
BR112012002333A2 (pt) 2009-08-06 2017-07-18 Neuraltus Pharmaceuticals Inc método de reduzir os efeitos colaterais e método de potencializar o efeito de um imunomodulador administrado a um sujeito que dele necessita; métodos para tratar doença associada com excesso de ativação de monócitos para macrófagos ativados, diabetes tipo ii ou complicações relacionadas, doença associada com a migração de monócitos ou macrófagos ativados, doença associada a excesso de produção de scd14 e/ou scd163 por macrófagos ativados; composto de cloreto de sódio; composição farmacêutica; método para diagnosticar uma doença relacionada com macrófagos em um sujeito; e método para determinar a eficácia do tratamento com um agente oxidante para uma doença relacionada a macrófagos em um sujeito.
US8465727B2 (en) 2009-10-06 2013-06-18 University of Pittsburgh—of the Commonwealth System of Higher Education Biomarkers for the diagnosis of ALS
JP2014081205A (ja) * 2012-10-12 2014-05-08 Fujikura Kasei Co Ltd Ｃ−反応性タンパク質測定用の測定試薬および測定方法
US20140147856A1 (en) 2012-11-29 2014-05-29 Rush University Medical Center Intestinal Permeability Assay for Neurodegenerative Diseases
RU2653754C2 (ru) 2012-12-06 2018-05-14 Пин Фарма, Инк. Лечение воспалительных, аутоиммунных и нейродегенеративных нарушений иммуннодепрессивными полипетидами, являющимися производными тат
CA3112130A1 (en) 2013-07-11 2015-01-15 University Of North Texas Health Science Center At Fort Worth Blood-based screen for detecting neurological diseases in primary care settings
EP3116481A1 (en) * 2014-03-13 2017-01-18 Vasilios VOUDOURIS Bendamustine solid dispersions and continuous infusion
EP3142674A4 (en) * 2014-05-16 2018-01-17 Neuraltus Pharmaceuticals, Inc. Methods and compositions for treatment of macrophage-related disorders
WO2017079161A2 (en) 2015-11-02 2017-05-11 Neuraltus Pharmaceuticals, Inc. Treatment of neurodegenerative disease with sodium chlorite
US20190060359A1 (en) 2015-11-02 2019-02-28 Neuraltus Pharmaceuticals, Inc. Treatment of neurodegenerative disease with sodium chlorite
AU2022277010A1 (en) 2021-05-18 2023-12-14 Rijksuniversiteit Groningen Nanopore proteomics
EP4412624A4 (en) 2021-10-04 2025-08-20 Neuvivo Inc TREATMENT METHODS FOR ALS PATIENTS
JP2025518096A (ja) 2022-05-27 2025-06-12 エレドン ファーマシューティカルズ，インコーポレイテッド 筋萎縮性側索硬化症の治療方法

Also Published As

Publication number Publication date
JP2024533873A (ja) 2024-09-12
GB2626503A (en) 2024-07-24
EP4412624A1 (en) 2024-08-14
WO2023060097A1 (en) 2023-04-13
EP4412624A4 (en) 2025-08-20
AU2022360976A1 (en) 2024-05-02
GB202406210D0 (en) 2024-06-19
US20230190790A1 (en) 2023-06-22
US12329776B2 (en) 2025-06-17

Similar Documents

Publication Publication Date Title
US12329776B2 (en) Treatment methods for ALS patients
EP1622629B1 (en) Controlled-release composition containing a strontium salt
US20070203141A1 (en) Method for administering birb 796 bs
EP3380095B1 (en) Compositions and methods for treating ischemic stroke
US10398713B2 (en) Compositions and methods for the treatment of neurodegenerative and other diseases
EP4275750A2 (en) Treatment of alzheimer's disease in a particular patient population
US12398093B2 (en) Compounds and methods for treating inflammatory disorders
US20110015276A1 (en) Therapeutical uses of inecalcitol
Kakad et al. Effect of hydrophilic polymer and binder on drug release of metformin HCl sustained release tablet
EP4199922B1 (en) (1r,3s)-3-((5-cyano-4-phenylthiazol-2-yl)carbamoyl)cyclopentane-1-carboxylic acid for use in the treatment of airway diseases
EP2366393B1 (en) Roflumilast for the treatment of pulmonary hypertension
EP3706867B1 (en) Combination of baclofen and chlorzoxazone for treatment of cerebellar ataxia
WO2021064589A1 (en) Intranasal pharmaceutical compositions of cyclobenzaprine
CN118382445A (zh) 用于als患者的治疗方法
EP0294940A1 (en) Pharmaceutical compositions
US12390439B2 (en) Oral liquid formulation of methocarbamol
US20230390331A1 (en) Biomarkers For Neurogenerative Disease
HK40091313A (en) (1r,3s)-3-((5-cyano-4-phenylthiazol-2-yl)carbamoyl)cyclopentane-1-carboxylic acid for use in the treatment of airway diseases
HK40091313B (en) (1r,3s)-3-((5-cyano-4-phenylthiazol-2-yl)carbamoyl)cyclopentane-1-carboxylic acid for use in the treatment of airway diseases
JPH072674A (ja) 白血病治療剤
EP4559463A1 (en) Edaravone or its salts for use in the treatment of oxidative stress-mediated neurodegenerative disorders
HK40103020A (zh) 用於治疗睡眠呼吸障碍(sdb)的l-pag衍生物
JP2025540537A (ja) フレカイニド含有液体医薬組成物及びその調製のためのプロセス
US20050261349A1 (en) Medicine for prevention or treatment of diabetes
HK40094581A (en) Treatment of alzheimer's disease in a particular patient population

Legal Events

Date Code Title Description
MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 2ND ANNIV.) - STANDARD

Year of fee payment: 2

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20240927

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20240927